CSIMarket
 
Vaccinex Inc   (VCNX)
Other Ticker:  
 
 
Price: $8.2000 $0.15 1.863%
Day's High: $8.73 Week Perf: 0.74 %
Day's Low: $ 8.06 30 Day Perf: 837.14 %
Volume (M): 3 52 Wk High: $ 10.10
Volume (M$): $ 24 52 Wk Avg: $1.15
Open: $8.06 52 Wk Low: $0.11



 Market Capitalization (Millions $) 37
 Shares Outstanding (Millions) 5
 Employees -
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) 3
 Cash Flow (TTM) (Millions $) -7
 Capital Exp. (TTM) (Millions $) 0

Vaccinex Inc
Vaccinex Inc is a clinical-stage biotechnology company that focuses on the discovery and development of novel therapeutic antibodies for the treatment of cancer and neurodegenerative diseases. The company uses its proprietary antibody discovery platform, called ActivMAb, to identify and develop antibodies that can selectively target and neutralize specific disease-causing proteins.
Vaccinex has a particular expertise in the development of antibodies that target the CXCL13 chemokine, which is found in high levels in the tumor microenvironment in various cancers. By targeting CXCL13, Vaccinex aims to disrupt the tumor microenvironment and enhance the body's immune response to fight cancer.
In addition to its cancer programs, Vaccinex is also exploring the therapeutic potential of its antibodies in neurodegenerative diseases such as Huntington's disease and Alzheimer's disease. The company's pipeline includes several antibody candidates in various stages of preclinical and clinical development.
Vaccinex has ongoing collaborations with pharmaceutical companies and research institutions to further advance its antibody programs. The company's goal is to develop innovative antibody-based therapies that can improve patient outcomes and address significant unmet medical needs.


   Company Address: 1895 Mount Hope Avenue Rochester 14620 NY
   Company Phone Number: 271-2700   Stock Exchange / Ticker: NASDAQ VCNX
   VCNX is expected to report next financial results on March 30, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Contract

Vaccinex Expands Access to ActivMAb Antigen Virus Technology Through Eight New Agreements

Published Wed, Feb 21 2024 1:00 PM UTC

In a breakthrough announcement, Vaccinex Inc., a renowned clinical-stage biotechnology company, has unveiled multiple strategic agreements that grant access to their cutting-edge ActivMAb Antigen Virus Technology. These new agreements mark a significant development in the field of antibody discovery and demonstrate Vaccinex's commitment to advancing the discovery and develop...

Shares

Vaccinex, Inc. Reverse Stock Split: A Boost or a Bust for Investors?

Published Thu, Feb 15 2024 1:01 PM UTC

Vaccinex, Inc. Announces Reverse Stock Split: What This Means for Investors
In a press release issued on February 15, 2024, Vaccinex, Inc. (NASDAQ: VCNX) announced a 1-for-14 reverse stock split of its issued common stock. This means that for every 14 shares of VCNX stock owned, shareholders will receive one share in return. The reverse stock split will be effective at 5...

Financing Agreement

Vaccinex Announces Pricing of $3.7 Million PIPE Financing to Accelerate Research in Neurodegenerative Disease Treatmentnn

Published Wed, Feb 7 2024 1:01 PM UTC

ROCHESTER, N.Y., Feb. 07, 2024 Vaccinex, Inc. (Nasdaq: VCNX) (Vaccinex or the Company) has made a significant announcement today regarding a private placement transaction. The clinical-stage biotechnology company, known for its innovative approach to treating neurodegenerative diseases, has successfully priced a $3.7 million financing round with a lead investment from a ...

Management Announcement

Vaccinex Granted Nasdaq Extension Amidst Strong Q3 2023 Performance, Boosting Investor Confidence

Published Mon, Dec 4 2023 1:00 PM UTC



In a recent development, Vaccinex Inc, the renowned biotechnology company, has been granted an extension until March 4, 2024, by the Nasdaq stock exchange to regain compliance with its listing rule. The listing rule in question pertains to the minimum bid price requirement. Vaccinex has reassured Nasdaq that it is taking necessary measures to meet this requirement...

Vaccinex Inc

Major Pharmaceutical Company Faces Uphill Battle in Q3 2023: A Closer Look at Vaccinex Inc's Struggles

Vaccinex Inc, a major pharmaceutical preparations company, recently announced the successful completion of Phase 1/2a randomized SIGNAL-AD study of Pepinemab in Alzheimer's Disease, reaching full accrual. This represents a significant milestone in the company's efforts to develop a therapeutic solution for a disease affecting millions worldwide.
However, this positive development comes at a challenging time for Vaccinex Inc, as evidenced by its disastrous third-quarter financial report for 2023. The company reported a staggering 60% revenue decline to just $0.02 million, accompanied by a widening shortfall per share to -$1.09. This decline is in stark contrast to the comparable reporting season a year earlier, where the company reported a shortfall per share of -$0.12 and zero revenue.






 

Vaccinex Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com